



# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Liu et al.

**SERIAL NO.:** 

10/643,752

**GROUP NO.:** 

1637

FILING DATE:

August 19, 2003

**EXAMINER:** 

Jezia Riley

TITLE:

**Evolving New Molecular Function** 

## CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any document(s) referred to as enclosed herein, is/are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 8th day of June, 2005.

Carrah Malone

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

### Submitted herewith is/are:

- 1. Transmittal Form (1 page);
- 2. Supplemental Information Disclosure Statement (3 pages);
- 3. Form PTO 1449 (1 page);
- 4. Copy of cited reference C218; and
- 5. Return Receipt Postcard.

VER 9/00

15 P. S. C.											
10 10	Application	Serial Number	10/6	10/643,752							
JUN 1 0 2005 E		Filing Date		Augi	August 19, 2003						
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	First Named	Inventor	Liu	Liu							
FORM		Group Art U	Init	1637	1637						
		Examiner N	ame	Jezia	Jezia Riley						
		Attorney Do	cket No.	LS5-	LS5-001						
		Patent No.		Not :	applicable						
	Issue Date	- <u></u>	Not :	Not applicable							
ENCLOSURES (check all that apply)											
Fee Transmittal Form	EN		e to File Missing		Notice of Appeal to Board						
Tee Transmittar Form		Parts of Applie		_	of Patent Appeals and						
Charle America				Interfe	rences						
☐ Check Attached☐ Copy of Fee Transmittal Form		Formal Drawin	ng(s)		Appeal Brief (in triplicate)						
Amendment/Response		Request For C			Status Inquiry						
☐ Preliminary ☐ After Final		Transmittal		$\boxtimes$	Return Receipt Postcard						
☐ Affidavits/declaration(s) ☐ Letter to Official		Power of Attor	rney Prior Powers)	$\boxtimes$	Certificate of First Class Mailing						
Draftsperson		(Revocation of	riioi roweis)		under 37 C.F.R. 1.8						
including Drawings [Total Sheets]		Terminal Disc	laimer		Certificate of Facsimile Transmission under 37 C.F.R. 1.8						
Petition for Extension of Time			aration and Power Utility or Design tion		Additional Enclosure(s) (please identify below)						
Supplemental Information Disclosure Statement		Small Entity Statement									
		_									
Copy of Supp. IDS Citation C218		CD(s) for large	table or computer								
Certified Copy of Priority Document(s)		Amendment A	fter Allowance	:							
Sequence Listing submission		Request for Correction	ertificate of								
☐ Paper Copy/CD	☐ Certificate	of Correction (in									
☐ Computer Readable Copy☐ Statement verifying		duplicate)									
identity of above											
CORRESPONDENCE ADDRESS	-		SIGNATURE BL	оск							
Direct all correspondence to: Patent A			-	Respectfully submitted,							
Goodwir				DM. Sul 1							
Exchang Boston, 1		Date: June 8, 2005		No problem							
Tel. No.:		Reg. No. 38,678 Tel. No.: (617) 570	-1299	Duncan A. Greenhalgh Attorney for Applicant							
Fax No.: (617) 523-1231 Customer No. 051414			Fax No.: (617) 523-		Goodwin Procter LLP Exchange Place						

Exchange Place Boston, MA 02109

VER 12/00



#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Liu et al.

CONF. NO.:

4082

**SERIAL NO.:** 

10/643,752

**GROUP NO.:** 

1637

FILING DATE:

August 19, 2003

**EXAMINER:** 

Jezia Riley

TITLE:

**Evolving New Molecular Function** 

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. In accordance with 37 C.F.R. 1.98(a)(2), only copies of the foreign patent documents and non-patent publications are enclosed.

In addition, Applicants wish to inform the Examiner about the following U.S. patent applications and the contents of their file wrappers, including all Office actions issued therein:

- 1. U.S.S.N. 11/141,542, entitled "Evolving New Molecular Function," filed on May 31, 2005; and
- 2. U.S.S.N. 11/141,164, entitled "Evolving New Molecular Function," filed on May 31, 2005.

Information about other patent applications can be found in Applicant's Information Disclosure Statement filed on May 6, 2005.

Serial No. 10/643,752

Page 2 of 3

### REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):  $\boxtimes$ within three (3) months of the filing date of a national application other than a (1) continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. 1.114; or after the period defined in (1) but before the mailing date of a final action or a notice (2) of allowance under 37 C.F.R. 1.311, and the requisite Statement is below, OR the requisite fee under 37 C.F.R. 1.17(p), namely \$180.00, is included herein, or after the mailing date of a final action or notice of allowance but before the payment (3) of the issue fee, AND the requisite Statement is below, AND П the requisite petition fee under 37 C.F.R. 1.17(p), namely \$180.00 is included herein. It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application. **STATEMENT** As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]: Each item of information contained in the Information Disclosure Statement was 1. first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after

Supplemental Information Disclosure Statement Serial No. ·10/643,752 Page 3 of 3

making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Date: June 8, 2005 Reg. No. 38,678

Tel. No.: (617) 570-1299 Fax No.: (617) 523-1231

VER 11/03 2466309 Respectfully submitted,

Duncan A. Greenhalgh Attorney for Applicants Goodwin Procter LLP Exchange Place

Boston, Massachusetts 02109

Customer No. 051414



FORM PTO - 1449						ATTORNEY DOCKET NO.: LS5-001  APPLICANT(S): Liu et al.  SERIAL NO.: 10/643,752						
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT												
					S							
						FILING DATE: August 19, 2003 GROUP: 1637						
	•		U.S.	PATE	1T I	OCUME	NTS					
EXAM. INIT.		DOCUMENT NUMBER	DATE	NA	NAME			CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
	A71	2003/0099945	05/29/200	03 Eat	on et	al.				07/30	/2001	
	A72	6,048,698	04/11/200	00 Eat	Eaton et al.					09/21	/1998	
	A73	5,858,660	01/12/199	99 Eat	Eaton et al.					03/20/1996		
	A74	5,723,289	03/03/199	98 Eat	on et	et al.				09/20/1994		
			FOREIC	ON PAT	ΓEN	T DOCUM	MENTS	3				
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUB CLASS	FILING DATE	G ABSTI ONLY		ENGLISH LANG (Y/N)	
		C	THER AR	T, JOU	RN	L ARTIC	LES, I	ETC.				
EXAM. INIT.	ОТН	ER DOCUMENTS	: (Including	Author,	Title	, Date, Rele	vant Pag	ges, Place o	f Publicat	ion)		
	C218 Dewey et al., "Integrated drug discovery technology in a test tube," www.currentdrugdiscovery.com (July 2002)											
EXAMINER					DATE CONSIDERED							

VER 9/00